If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Proof of Concept Programme

11 Dec 2007 11:18

Imperial Innovations Group plc11 December 2007 Imperial Innovations Group plc ("Imperial Innovations") Proof of Concept programme Imperial Innovations Group plc (AIM: IVO) today announces the creation of a newUS$1 million Proof of Concept ("PoC") programme which has been funded byShapoorji Pallonji & Company Limited ("SPCL") a diversified conglomerateincluding the oldest construction company based in India. The objective of the PoC programme is to validate and accelerate the developmentof emerging technologies at Imperial College London for spin-out opportunities.Imperial Innovations will manage the programme including the recommendation,selection, and commercial assessment of the projects. The company isparticularly interested in developing technologies with SPCL which may lead tomarket applications and follow-on joint development opportunities in India. The PoC programme will fund three to five technologies of twelve to eighteenmonths' duration over the next two years and will give priority to applicationsin the built environment, whether renewable energy or energy-efficiencyinnovations. The creation of the PoC programme with SPCL builds on Imperial Innovations'ongoing activities in India which is regarded as one of the most importanttechnology markets for the future, including the recent formation of i2india,the technology commercialisation company based in India. Susan Searle, CEO of Imperial Innovations said: "The launch of the Shapoorji Proof of Concept programme will help us qualifyinventions in our intellectual property portfolio for more focused spin-outopportunities. Pre-commercial funding is very difficult to obtain forearly-stage technologies therefore we are extremely grateful for the fundingSPCL has provided. We are also encouraged that influential companies such asSPCL turn to us to access next generation technologies." Mr. Pallonji Mistry, Chairman of Shapoorji Pallonji & Co. Ltd., Mumbai said: "We look forward to a mutually rewarding and long term relationship withImperial Innovations through promoting development projects in selected areas." -Ends- For more information contact: Imperial InnovationsSusan Searle, Chief Executive Officer +44 (0)20 7594 6591Lucy Ahfong, Marketing Communications Executive +44 (0)20 7594 6644 M:CommunicationsPatrick d'Ancona / Eleanor Williamson +44 (0)20 7153 1539 JPMorgan Cazenove (NOMAD to Imperial Innovations)Steve Baldwin +44(0)20 7588 2828 Notes to Editors About Imperial Innovations Imperial Innovations is one of the UK's leading technology transfer andcommercialisation companies. The company was founded in 1986 and its ordinaryshares admitted to trading on the AIM Market of London Stock Exchange plc inJuly 2006, raising £25 million at an offer price of 365p and £1 million by meansof a public offer. In November 2007, the company raised a further £30 million bymeans of a placing of new ordinary shares with investors. The company's integrated approach encompasses the identification of ideas,protection of intellectual property, development and licensing of technology andformation, incubation and investment in technology businesses. A wide range oftechnologies are commercialised within the areas of healthcare, energy,environment and emerging technology trends. Based at Imperial College London, the company has established equity holdings in74 technology businesses and is managing 133 commercial agreements as of 31 July2007. Imperial Innovations also commercialises technologies originating fromoutside Imperial College through incubation contracts with the Carbon Trust andWRAP and has commercialisation contracts with a number of multinationalcorporations including BAE Systems. www.imperialinnovations.co.uk About Shapoorji Pallonji & Company Ltd Shapoorji Pallonji & Company Ltd is a diversified conglomerate with businessinterests in the construction, finance, biotechnology, and energy sectors. Thecompany started 140 years ago in Mumbai as a construction company. ShapoorjiPallonji has grown from its origins as India's oldest construction company andhas developed an international reputation in delivering complex projectsincluding factories, nuclear research establishments, nuclear waste handling,scientific and research establishments, stadia and auditoria, airports, hotels,hospitals, giant skyscrapers, housing complexes, townships, water treatmentplants, roads, expressways, power plants and biotech facilities. It is thelargest private shareholder (18.5%) of TATA SONS Ltd, the Holding Company of theTATA Group. The annual turnover of the TATA Group is over US$15 billion. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Sep 20162:40 pmRNSHolding(s) in Company
24th Aug 20167:01 amRNSCell Medica and UCL collaboration
12th Jul 20167:02 amRNSCell Medica acquires Delenex Therapeutics
6th Jul 20167:00 amRNSEconic raises £5m to develop novel catalyst tech
30th Jun 201612:11 pmRNSPsiOxus and Bristol-Myers Squibb collaboration
28th Jun 20167:00 amRNSStorm Therapeutics raises £12m
21st Jun 20164:35 pmRNSPrice Monitoring Extension
21st Jun 20167:00 amRNSDirector's share purchase
20th Jun 20167:03 amRNSCircassia cat allergy Phase III study
17th Jun 20167:00 amRNSCell Medica and Baylor College of Medicine partner
16th Jun 201610:44 amRNSReplacement Holding(s) in Company
14th Jun 20163:20 pmRNSEdison issues outlook on Imperial Innovations)
14th Jun 20169:00 amRNSHolding(s) in Company
13th Jun 20167:00 amRNSAllotment of Deferred Placing Shares
31st May 20167:00 amRNSFeaturespace closes £6.2 million funding round
26th May 20167:00 amRNS£3 million funding round for Inflowmatix
11th May 201612:32 pmRNSDavid Newlands appointed Chairman
4th May 20164:35 pmRNSPrice Monitoring Extension
4th May 201611:08 amRNSNexeon raises £30m, plans development lab in Asia
4th May 20167:00 amRNSAnalyst and Investor day
29th Apr 20164:35 pmRNSPrice Monitoring Extension
29th Apr 201612:42 pmRNSSale of Innovations portfolio Stanmore Implants
7th Apr 20167:00 amRNSHalf Yearly Report
21st Mar 20167:00 amRNSDr Martin Knight to step down from the board
18th Mar 201612:40 pmRNSNotice of Results
17th Mar 20167:00 amRNSTopiVert reports successful Phase I clinical study
26th Feb 20168:39 amRNSHolding(s) in Company
25th Feb 20163:59 pmRNSHolding(s) in Company
25th Feb 20163:50 pmRNSHolding(s) in Company
25th Feb 20168:53 amRNSHolding(s) in Company
22nd Feb 20165:01 pmRNSAdmission of shares to trading on AIM
22nd Feb 201612:29 pmRNSResult of General Meeting
22nd Feb 20167:00 amRNS£13.5m funding round in Precision Ocular
11th Feb 20162:51 pmRNSHolding(s) in Company
8th Feb 20167:00 amRNSInnovations leads £5m Series A round in Aqdot
4th Feb 20166:08 pmRNSResult of Placing
4th Feb 20167:00 amRNSPlacing to raise £100 million
2nd Feb 20167:00 amRNSMISSION Therapeutics raises £60 million
26th Jan 20167:00 amRNSInivata completes £31.5m Series A funding round
25th Jan 20167:00 amRNSInnovations joins Apollo consortium
18th Jan 20167:00 amRNSInnovations invests £25m in new £50m UCL Tech Fund
2nd Dec 20157:00 amRNSKesios Therapeutics raises £19 million
19th Nov 20151:51 pmRNSResult of AGM
4th Nov 20151:40 pmRNSGrant of share options
28th Oct 20157:00 amRNSPosting of Annual Report and Notice of AGM
22nd Oct 20157:00 amRNSLeads £1.5m seed funding into AI pioneer, Telectic
14th Oct 20157:00 amRNSFinal Results
22nd Sep 20154:10 pmRNSNotice of Results
12th Aug 20157:00 amRNSIssue of Equity
4th Aug 20157:01 amRNS£2.5m funding round in Oxford Biotrans

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.